MIMETAS Revenue and Competitors
Estimated Revenue & Valuation
- MIMETAS's estimated annual revenue is currently $23.1M per year.
- MIMETAS's estimated revenue per employee is $170,000
Employee Data
- MIMETAS has 136 Employees.
- MIMETAS grew their employee count by -1% last year.
MIMETAS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.1M | 26 | 4% | N/A | N/A |
#2 | $52.4M | 280 | 23% | N/A | N/A |
#3 | $5.4M | 40 | -7% | N/A | N/A |
#4 | $4.6M | 34 | 0% | N/A | N/A |
#5 | $5.7M | 42 | -5% | N/A | N/A |
#6 | $23.1M | 136 | -1% | N/A | N/A |
#7 | $67.6M | 313 | 15% | $31.5M | N/A |
#8 | $1.7M | 17 | 6% | N/A | N/A |
#9 | $20.4M | 120 | -1% | N/A | N/A |
What Is MIMETAS?
High-throughput Human Disease and Tissue Models MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
keywords:N/A
N/A
Total Funding
136
Number of Employees
$23.1M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MIMETAS's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Principal Scientist | Reveal Email/Phone |
2 | Biomaterials Manager | Reveal Email/Phone |
3 | CEO & co-founder | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
5 | Associate Director Sales | Reveal Email/Phone |
6 | Associate Director / Head fee-for-service department | Reveal Email/Phone |
7 | VP Biology | Reveal Email/Phone |
8 | MSCA-ESR, PhD candidate | Reveal Email/Phone |
9 | Director Biology Discovery | Reveal Email/Phone |
10 | Scientific project lead | Reveal Email/Phone |
MIMETAS News
CN Bio Tissues, Mimetas Insphero, Ascendance Bio, Kirkstall , Hurel , Synvivo , Axosim and Nortis. This Organs-on-chips Market report covers...
LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in...
Mimetas BV participating in 325m cancer funding. © Oncode Institute. 20.04.2022 by tg. Organ-on-chip disease model specialist Mimentas BV participates in a...
Emulate, CN Bio, Tissuse, Mimetas, Insphero, Ascendance Bio, Kirkstall, Hurel, Synvivo, Axosim, Nortis. Geographical Analysis: North America, ...
... Analysis, Technology and Global Industry Trends by 2027 Top Key Vendors-REPROCELL, 3D Biotek, Nano3D Biosciences, MIMETAS.
Other Companies in Leiden
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21.2M | 137 | 49% | N/A |
#2 | $25.4M | 165 | -1% | N/A |
#3 | $35M | 196 | 6% | N/A |
#4 | $31.9M | 200 | -14% | N/A |
#5 | $44.6M | 225 | 6% | N/A |